Sign up to save your podcasts
Or
Share Highlights AACR 2026 - EN
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Highlights AACR 2026 - EN
In this episode, Dr. Ángela Lamarca, Medical Oncologist at Hospital Universitario Fundación Jiménez Díaz (Madrid), shares some of the most relevant updates presented at the AACR (American Association for Cancer Research), held in San Diego, marking a hopeful moment in the management of pancreatic adenocarcinoma.
She comments on very promising results from two first-line studies in patients with mKRAS, both with the pan-KRAS inhibitor daraxonrasib.
The first, daraxonrasib as monotherapy, shows an overall response rate of 47%, a disease control rate of 92%, and a 6-month progression-free survival (PFS) of 71%. https://eppro01.ativ.me/appinfo.php?page=Session&project=AACR26&id=P11375
The second, daraxonrasib + GemNab-paclitaxel (GI-102 platform), achieves an overall response rate of 58%, a disease control rate of 90%, and a 6-month PFS of 84%. https://eppro01.ativ.me/appinfo.php?page=Inthtml&project=AACR26&id=7240
The episode also reviews other ongoing clinical trials, such as the phase III RASolute 303 study, which compares daraxonrasib monotherapy versus standard chemotherapy (gemcitabine + nab-paclitaxel) and their combination.
Finally, it discusses the RASolute 302 trial (https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/), whose data will be presented at ASCO (American Society of Clinical Oncology) 2026.
An episode that offers a rigorous and up-to-date overview, conveying a message of optimism and inviting a deeper look into data that could mark a turning point in pancreatic cancer.
--------
3rd Edition TooMore Gi is also available at: transworldeditors.com/toomore-gi-3/
The purpose of this podcast is to provide continuing medical education and to inform healthcare professionals.
This is not a substitute for professional healthcare and is not intended to be used in the diagnosis or treatment of specific cases. Participants express their own opinions, experiences, and conclusions.
View all episodes
By Transworld HealthIn this episode, Dr. Ángela Lamarca, Medical Oncologist at Hospital Universitario Fundación Jiménez Díaz (Madrid), shares some of the most relevant updates presented at the AACR (American Association for Cancer Research), held in San Diego, marking a hopeful moment in the management of pancreatic adenocarcinoma.
She comments on very promising results from two first-line studies in patients with mKRAS, both with the pan-KRAS inhibitor daraxonrasib.
The first, daraxonrasib as monotherapy, shows an overall response rate of 47%, a disease control rate of 92%, and a 6-month progression-free survival (PFS) of 71%. https://eppro01.ativ.me/appinfo.php?page=Session&project=AACR26&id=P11375
The second, daraxonrasib + GemNab-paclitaxel (GI-102 platform), achieves an overall response rate of 58%, a disease control rate of 90%, and a 6-month PFS of 84%. https://eppro01.ativ.me/appinfo.php?page=Inthtml&project=AACR26&id=7240
The episode also reviews other ongoing clinical trials, such as the phase III RASolute 303 study, which compares daraxonrasib monotherapy versus standard chemotherapy (gemcitabine + nab-paclitaxel) and their combination.
Finally, it discusses the RASolute 302 trial (https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/), whose data will be presented at ASCO (American Society of Clinical Oncology) 2026.
An episode that offers a rigorous and up-to-date overview, conveying a message of optimism and inviting a deeper look into data that could mark a turning point in pancreatic cancer.
--------
3rd Edition TooMore Gi is also available at: transworldeditors.com/toomore-gi-3/
The purpose of this podcast is to provide continuing medical education and to inform healthcare professionals.
This is not a substitute for professional healthcare and is not intended to be used in the diagnosis or treatment of specific cases. Participants express their own opinions, experiences, and conclusions.